- Home
- HRMY vs SLVM Comparison
HRMY vs SLVM Comparison
Compare HRMY & SLVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | SLVM |
|---|---|---|
| Founded | 2017 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | SLVM |
|---|---|---|
| Price | $35.24 | $47.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $50.56 | ★ $54.00 |
| AVG Volume (30 Days) | ★ 934.4K | 590.4K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | 3.17 | ★ 4.36 |
| Revenue | $825,944,000.00 | ★ $3,431,000,000.00 |
| Revenue This Year | $20.68 | N/A |
| Revenue Next Year | $15.93 | $2.29 |
| P/E Ratio | $11.14 | ★ $10.86 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $37.52 |
| 52 Week High | $40.93 | $93.79 |
Technical Indicators
Market Signals| Indicator | HRMY | SLVM |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 61.12 |
| Support Level | $32.77 | $44.08 |
| Resistance Level | $36.20 | $48.74 |
| Average True Range (ATR) | 1.11 | 1.91 |
| MACD | 0.17 | 0.33 |
| Stochastic Oscillator | 81.04 | 72.90 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.